Eleven entitled to
Under the terms of the agreement, Eleven could receive up to an
"With the completion of this licensing deal and the IND being effective, we look forward to the future clinical advancement of EBI-031 by Roche as they explore its potential use for ocular diseases, including diabetic macular edema," said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company, including statements about the potential
effectiveness of the license agreement or receipt of payments
thereunder, the future rights and obligations of the parties under the
license agreement, the Company's strategy, future operations,
advancement or maturation of its product candidates and product
pipeline, clinical development of the Company's product candidates,
including expectations regarding timing of regulatory submissions and
initiation of clinical trials, regulatory requirements for initiation of
clinical trials and registration of product candidates, the review of
its strategic alternatives and the outcome of such review, the results
of strategic transactions, the sufficiency of its cash resources and
other statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project,"
"target," "potential," "will," "would," "could," "should," "continue,"
and similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: the occurrence of any event, change or other circumstances
that could give rise to the termination of the license agreement, the
outcome of any legal proceedings that could be instituted against the
Company or its directors related to the license agreement, the inability
to consummate the transactions contemplated by the license agreement due
to the failure to obtain the requisite approval of the Company's
stockholders, the uncertainties inherent in the initiation and conduct
of clinical trials, availability and timing of data from clinical
trials, whether results of early clinical trials or preclinical studies
will be indicative of the results of future trials, the adequacy of any
clinical models, uncertainties associated with regulatory review of
clinical trials and applications for marketing approvals and other
factors discussed in the "Risk Factors" section of the Company's
quarterly report on Form 10-Q for the quarter ended
News Provided by Acquire Media